Submitted:
02 April 2025
Posted:
03 April 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Detailed Case Description
3. Discussion
4. Conclusion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Van Gelder, I.C.; Rienstra, M.; Bunting, K.V.; Casado-Arroyo, R.; Caso, V.; Crijns, H.J.G.M.; De Potter, T.J.R.; Dwight, J.; Guasti, L.; Hanke, T.; et al. 2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 2024, 45, 3314–3414. [Google Scholar] [CrossRef] [PubMed]
- Rienstra, M.; Tzeis, S.; Bunting, K.V.; Caso, V.; Crijns, H.J.G.M.; De Potter, T.J.R.; Sanders, P.; Svennberg, E.; Casado-Arroyo, R.; Dwight, J.; et al. Spotlight on the 2024 ESC/EACTS Management of Atrial Fibrillation Guidelines: 10 Novel Key Aspects. Europace 2024, 26, euae298. [Google Scholar] [CrossRef] [PubMed]
- Polymeris, A.A.; Meinel, T.R.; Oehler, H.; Hölscher, K.; Zietz, A.; Scheitz, J.F.; Nolte, C.H.; Stretz, C.; Yaghi, S.; Stoll, S.; et al. Aetiology, Secondary Prevention Strategies and Outcomes of Ischaemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. J Neurol Neurosurg Psychiatry 2022, 93, 588–598. [Google Scholar] [CrossRef] [PubMed]
- Galea, R.; Seiffge, D.; Räber, L. Atrial Fibrillation and Ischemic Stroke despite Oral Anticoagulation. JCM 2023, 12, 5784. [Google Scholar] [CrossRef] [PubMed]
- Amarenco, P.; Kim, J.S.; Labreuche, J.; Charles, H.; Abtan, J.; Béjot, Y.; Cabrejo, L.; Cha, J.-K.; Ducrocq, G.; Giroud, M.; et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med 2020, 382, 9–19. [Google Scholar] [CrossRef] [PubMed]
- Mazzolai, L.; Teixido-Tura, G.; Lanzi, S.; Boc, V.; Bossone, E.; Brodmann, M.; Bura-Rivière, A.; De Backer, J.; Deglise, S.; Della Corte, A.; et al. 2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases. European Heart Journal 2024, 45, 3538–3700. [Google Scholar] [CrossRef] [PubMed]
- Naylor, A.R.; Ricco, J.-B.; De Borst, G.J.; Debus, S.; De Haro, J.; Halliday, A.; Hamilton, G.; Kakisis, J.; Kakkos, S.; Lepidi, S.; et al. Editor’s Choice – Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery 2018, 55, 3–81. [Google Scholar] [CrossRef] [PubMed]
- Amarenco, P.; Hobeanu, C.; Labreuche, J.; Charles, H.; Giroud, M.; Meseguer, E.; Lavallée, P.C.; Gabriel Steg, P.; Vicaut, É.; Bruckert, E.; et al. Carotid Atherosclerosis Evolution When Targeting a Low-Density Lipoprotein Cholesterol Concentration <70 Mg/dL After an Ischemic Stroke of Atherosclerotic Origin. Circulation 2020, 142, 748–757. [Google Scholar] [CrossRef] [PubMed]
- Bogniotti, L.A.C.; Teivelis, M.P.; Cardozo, F.A.M.; Caramelli, B.; Wolosker, N.; Puech-Leão, P.; De Luccia, N.; Calderaro, D. Hemodynamic Depression after Carotid Surgery: Incidence, Risk Factors and Outcomes. Clinics 2022, 77, 100090. [Google Scholar] [CrossRef] [PubMed]
- Visseren, F.L.J.; Mach, F.; Smulders, Y.M.; Carballo, D.; Koskinas, K.C.; Bäck, M.; Benetos, A.; Biffi, A.; Boavida, J.-M.; Capodanno, D.; et al. 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal 2021, 42, 3227–3337. [Google Scholar] [CrossRef] [PubMed]
- Joseph, P.; Ishai, A.; Mani, V.; Kallend, D.; Rudd, J.H.F.; Fayad, Z.A.; Tawakol, A. Short-Term Changes in Arterial Inflammation Predict Long-Term Changes in Atherosclerosis Progression. Eur J Nucl Med Mol Imaging 2017, 44, 141–150. [Google Scholar] [CrossRef] [PubMed]
- Ibanez, B.; Fernández-Ortiz, A.; Fernández-Friera, L.; García-Lunar, I.; Andrés, V.; Fuster, V. Progression of Early Subclinical Atherosclerosis (PESA) Study. Journal of the American College of Cardiology 2021, 78, 156–179. [Google Scholar] [CrossRef] [PubMed]
- Visseren, F.L.J.; Mach, F.; Smulders, Y.M.; Carballo, D.; Koskinas, K.C.; Bäck, M.; Benetos, A.; Biffi, A.; Boavida, J.-M.; Capodanno, D.; et al. 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal 2021, 42, 3227–3337. [Google Scholar] [CrossRef] [PubMed]
- Rehberger Likozar, A.; Zavrtanik, M.; Šebeštjen, M. Lipoprotein(a) in Atherosclerosis: From Pathophysiology to Clinical Relevance and Treatment Options. Annals of Medicine 2020, 52, 162–177. [Google Scholar] [CrossRef] [PubMed]
- Leng, Y.; Hu, Q.; Ling, Q.; Yao, X.; Liu, M.; Chen, J.; Yan, Z.; Dai, Q. Periodontal Disease Is Associated with the Risk of Cardiovascular Disease Independent of Sex: A Meta-Analysis. Front. Cardiovasc. Med. 2023, 10, 1114927. [Google Scholar] [CrossRef] [PubMed]
- González L, Bulnes JF, Orellana MP, Muñoz Venturelli P, Martínez Rodriguez G. The Role of Colchicine in Atherosclerosis: From Bench to Bedside. Pharmaceutics 2022, 14, 1395. [CrossRef] [PubMed]
- Tucker B, Goonetilleke N, Patel S, Keech A. Colchicine in atherosclerotic cardiovascular disease. Heart. 2024, 110, 618–625. [CrossRef] [PubMed]




| Test | Result | Reference range |
| White Blood Cell Count | 9.81 10*3/uI | 4.00-10.0 10*3/uI |
| Hemoglobin | 14.1 g/dl | 12.6-17.4 g/dl |
| Platelet Count | 203 g/dl | 150-450 g/dl |
| Blood glucose | 94 mg/dl | 82-115 mg/dl |
| Total Cholesterol | 117 mg/dl | 0-200 mg/dl |
| Triglycerides | 108 mg/dl | 0-150 mg/dl |
| High-Density Lipoprotein Cholesterol | 49 mg/dl | 40-60 mg/dl |
| Low-Density Lipoprotein Cholesterol | 48.71 mg/dl | 10-100 mg/dl |
| Aspartate Transaminase | 30 U/L | 5-34 U/L |
| Alanine Transaminase | 13 U/L | 0-55 U/L |
| Total Bilirubin | 0.51 mg/dl | 0.2-1.2 mg/dl |
| Serum Urea | 25.00 mg/dl | 8.4-2.57 mg/dl |
| Serum Creatinine | 1.47 mg/dl | 0.72-1.25 mg/dl |
| Serum Uric Acid | 7.00 mg/dl | 3.5-7.2 mg/dl |
| C-Reactive Protein | 4.60 mg/L | 0-5.0 mg/L |
| Potassium | 4.50 mmol/L | 3.50-4.50 mmol/L |
| Sodium | 140 mmol/L | 135-145 mmol/L |
| Glomerular Filtration Rate | 51 mL/min/1.73m2 | 90-120mL/min/1.73m2 |
| Microalbuminuria | 10 mg/L | 0-10mg/L |
| Urinary Sediment Test | Negative | Negative |
| Test | Result | Reference range |
| White Blood Cell Count | 8.56 10*3/uI | 4.00-10.0 10*3/uI |
| Hemoglobin | 15.6 g/dl | 12.6-17.4 g/dl |
| Platelet Count | 197 g/dl | 150-450 g/dl |
| Blood Glucose | 96 mg/dl | 82-115 mg/dl |
| Total Cholesterol | 146 mg/dl | 0-200 mg/dl |
| Triglycerides | 75 mg/dl | 0-150 mg/dl |
| High-Density Lipoprotein Cholesterol | 61 mg/dl | 40-60 mg/dl |
| Low-Density Lipoprotein Cholesterol | 70 mg/dl | 10-100 mg/dl |
| Aspartate Transaminase | 25 U/L | 5-34 U/L |
| Alanine Transaminase | 15 U/L | 0-55 U/L |
| Total Bilirubin | 0.70 mg/dl | 0.2-1.2 mg/dl |
| Serum Urea | 22.00 mg/dl | 8.4-2.57 mg/dl |
| Serum Creatinine | 1.41 mg/dl | 0.72-1.25 mg/dl |
| Serum Uric Acid | 7.00 mg/dl | 3.5-7.2 mg/dl |
| C-Reactive Protein | 2.20 mg/L | 0-5.0 mg/L |
| Glomerular Filtration Rate | 54 mL/min/1.73m2 | 90-120mL/min/1.73m2 |
| Microalbuminuria | 9 mg/L | 0-10mg/L |
| Urinary Sediment Test | Negative | Negative |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).